Zobrazeno 1 - 10
of 1 769
pro vyhledávání: '"A Kivitz"'
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 675-689 (2024)
Abstract Introduction The aim of this work is to evaluate secukinumab vs. placebo in a challenging-to-treat and smaller US patient subpopulation of the international FUTURE 2–5 studies in patients with psoriatic arthritis (PsA). Methods Data were p
Externí odkaz:
https://doaj.org/article/82e8a3c103fb46598b98d83425a76465
Autor:
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 633-648 (2024)
Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had
Externí odkaz:
https://doaj.org/article/9ce4042ecece4341be994d1a7b7901c4
Autor:
Kivitz, Alan J.1 (AUTHOR) ajkivitz@yahoo.com, Kremer, Joel M.2 (AUTHOR), Legerton III, Clarence W.3 (AUTHOR), Pricop, Luminita4 (AUTHOR), Singhal, Atul5 (AUTHOR)
Publikováno v:
Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p675-689. 15p.
Autor:
Anisha B. Dua, Kerri Ford, Stefano Fiore, Dimitrios A. Pappas, Jud C. Janak, Taylor Blachley, Carla Roberts-Toler, Kelechi Emeanuru, Joel M. Kremer, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1753-1768 (2023)
Abstract Introduction This observational study evaluated response in patients with rheumatoid arthritis (RA) who switched from an interleukin-6 receptor inhibitor (IL-6Ri) to a Janus kinase inhibitor (JAKi) and vice versa. Methods Adult patients with
Externí odkaz:
https://doaj.org/article/ca669a2fb43c4128bbcdad8bd677d8d4
Publikováno v:
Patient Preference and Adherence, Vol Volume 17, Pp 2451-2461 (2023)
Alan Kivitz,1 Alicia M Ellis,2 Vishvesh Shende,3 Jérémy Lambert,4 Daljit Tatla2 1Altoona Center for Clinical Research, Duncansville, PA, USA; 2UCB Pharma, Raleigh, NC, USA; 3UCB Pharma, Slough, UK; 4UCB Pharma, Colombes, FranceCorrespondence: Dalji
Externí odkaz:
https://doaj.org/article/8371d2ec458141dda8f3573aa1871885
Autor:
Alan Kivitz, Alvin F. Wells, Juan I. Vargas, Herbert S. B. Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 901-915 (2023)
Abstract Introduction Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label ex
Externí odkaz:
https://doaj.org/article/9b7fbbcc263c40338f0904ba90e40d30
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alan Kivitz, Wesley DeHaan, Rehan Azeem, Justin Park, Sheri Rhodes, Jamie Inshaw, Sheldon S. Leung, Savvas Nicolaou, Lloyd Johnston, Takashi K. Kishimoto, Peter G. Traber, Earl Sands, Hyon Choi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 825-847 (2023)
Abstract Introduction SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6 mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered wi
Externí odkaz:
https://doaj.org/article/cf6f1cb3ba274f37b044035ffe0ee7d4
Autor:
Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R. Curtis
Publikováno v:
BMC Rheumatology, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Background Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators. This post hoc analysis eval
Externí odkaz:
https://doaj.org/article/c660845ad6064916b2d9ab800648486d